Clinical trials: Advanced Malignant Solid Tumours
Triple Negative Metastatic Breast Cancer, Advanced Ovarian Cancer
Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel
The purpose of this study is to identify a safe and tolerable dose of the drug KU-0059436 that can be given in combination with carboplatin and/or Paclitaxel chemotherapy.
- Conditions
- Triple Negative Metastatic Breast Cancer, Advanced Ovarian Cancer, Carboplatin, Paclitaxel
- Trial name
- NCT00516724
- Testing
- KU-0059436 (AZD2281)(PARP inhibitor), Carboplatin, Paclitaxel
- Where
- 4 sites in Belgium, Netherlands and 1 more
- Volunteers
- 189 people
- Sponsor
- AstraZeneca
Triple Negative Breast Cancer (TNBC), Advanced Solid Tumors Cancer
PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer
The primary purposes of this study are to determine the safety and tolerability of PQ203 in patients with advanced solid tumors including triple negative breast cancer (TNBC), and to determine a recommended Phase 2 dose level for…
- Trial name
- NCT07190469
- Testing
- PQ203
- Where
- 4 sites in United States, Canada
- Volunteers
- 80 people
- Sponsor
- ProteinQure Inc.
Colorectal Neoplasms, Stomach Neoplasms
SND002 Cell Injection in Participants With Advanced Malignant Solid Tumors
This is a phase 1, multicenter, open-label, single-arm study evaluating SND002 Cell Injection in participants with advanced malignant solid tumors that have progressed after standard treatment or for whom no standard treatment is…
- Conditions
- Colorectal Neoplasms, Stomach Neoplasms, Solid Tumor Malignancies
- Trial name
- NCT07903857
- Testing
- SND002 Cell Injection
- Where
- 2 sites in China
- Volunteers
- 78 people
- Sponsor
- Guizhou Sinorda Pharmaceutical Co., Ltd.
Advanced Malignant Solid Tumors
A Clinical Study of 9MW2821 in Advanced Malignant Solid Tumors
This study is a Phase 1, first-in-human, open-label, dose-escalation and cohort expansion study designed to characterize the safety, tolerability, pharmacokinetics, preliminary antitumor activity and immunogenicity of 9MW2821…
- Trial name
- NCT05773937
- Testing
- 9MW2821
- Where
- 2 sites in China
- Volunteers
- 40 people
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Solid Tumor, Triple-negative Breast Cancer
A Study of LY3435151 in Participants With Solid Tumors
The reason for this study is to see if the study drug LY3435151 is safe in participants with advanced solid tumors.
- Conditions
- Solid Tumor, Triple-negative Breast Cancer, Gastric Adenocarcinoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT04099277
- Testing
- LY3435151, Pembrolizumab
- Where
- 2 sites in United States, Japan
- Volunteers
- 2 people
- Sponsor
- Eli Lilly and Company
Solid Tumor
A Study of RC148 As a Single Agent and Combination Therapy in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors
The primary objective of Phase I of this trial is to evaluate the safety, tolerability, maximum tolerated dose (MTD)/maximum administered dose (MAD) of RC148 in patients with locally advanced unresectable or metastatic solid…
- Trial name
- NCT06016062
- Testing
- RC148 Monotherapy, RC148+docetaxel Combination Therapy, RC148+RC48 Combination Therapy
- Where
- 31 sites in China
- Volunteers
- 221 people
- Sponsor
- RemeGen Co., Ltd.
Advanced Malignant Solid Tumors, TGCT
Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCT
To evaluate the safety and tolerability of HMPL-653 in patients with advanced solid tumors who have failure of standard of care or can not tolerate standard of care or those with TGCT, and to determine the maximum tolerated dose…
- Trial name
- NCT05277454
- Testing
- HMPL-653
- Where
- 5 sites in China
- Volunteers
- 113 people
- Sponsor
- Hutchison Medipharma Limited
Solid Tumors
A Study of RC48-ADC in Subjects With HER2-Positive Advanced Malignant Solid Tumors
A Phase I Study to Evaluate the Safety,Tolerability and Pharmacokinetics of RC48-ADC for Injection in Subjects With Advanced Malignant Solid Tumors With HER2-positive
- Trial name
- NCT02881138
- Testing
- RC48-ADC
- Where
- China
- Volunteers
- 24 people
- Sponsor
- RemeGen Co., Ltd.
Malignant Neoplasm, Carcinoma, Merkel Cell
A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)
Researchers are looking for new ways to treat people with solid tumors, lymphomas (blood cancers), and a certain type of skin cancer.
- Conditions
- Malignant Neoplasm, Carcinoma, Merkel Cell, Lymphoma
- Trial name
- NCT07302347
- Testing
- Pembrolizumab
- Where
- 7 sites in Japan
- Volunteers
- 20 people
- Sponsor
- Merck Sharp & Dohme LLC
Solid Tumor
A Study of Neoantigen mRNA Personalised Cancer in Patients With Advanced Solid Tumors
This is a Phase 1 open label study to evaluate the tolerability, safety, immunogenicity, and efficacy of SW1115C3, a neoantigen mRNA personalised cancer vaccine, in patients with advanced malignant solid tumours.
- Trial name
- NCT05198752
- Testing
- Neoantigen mRNA Personalised Cancer SW1115C3
- Where
- 3 sites in Australia, Austria
- Volunteers
- 30 people
- Sponsor
- Stemirna Therapeutics
Advanced Solid Tumor
A Study of SHR-4602 in Subjects With Advanced Malignant Solid Tumors
This is an open-label, three-part study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of SHR-4602 and preliminary anti-tumor efficacy in HER2 expressing or mutated advanced malignant solid tumor…
- Trial name
- NCT05819684
- Testing
- SHR-4602 for injection
- Where
- China
- Volunteers
- 133 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Malignant Mesothelioma, Colorectal Cancer
Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors
This is a first-in-human, single-arm, open-label, dose escalation clinical study to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic characteristics, immunogenicity and preliminary efficacy of UCMYM802…
- Conditions
- Malignant Mesothelioma, Colorectal Cancer, Bile Duct Cancer, Rectal Cancer
- Trial name
- NCT06256055
- Testing
- UCMYM802 Injection
- Where
- China
- Volunteers
- 24 people
- Sponsor
- UTC Therapeutics Inc.
Advanced Malignant Solid Tumor
A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Properties and Preliminary Efficacy of 9MW3811 in Patients With Advanced Solid Tumors
This is a single ascending dose study of 9MW3811, the primary objective of which is to evaluate the safety, tolerability and preliminary efficacy of 9MW3811 in patients with advanced solid tumors.
- Trial name
- NCT05911984
- Testing
- 9MW3811 Injection
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Multiple Myeloma, Diffuse Large B-Cell Lymphoma
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
The main purpose of this first human study with CC-223 is to assess the safety and action of a new class of experimental drug (dual mTOR inhibitors) in patients with advanced tumors unresponsive to standard therapies and to…
- Conditions
- Multiple Myeloma, Diffuse Large B-Cell Lymphoma, Glioblastoma Multiforme, Hepatocellular Carcinoma
- Trial name
- NCT01177397
- Testing
- CC-223
- Where
- 16 sites in United States, France and 2 more
- Volunteers
- 226 people
- Sponsor
- Celgene
Advanced Malignant Solid Tumors
Study of PKI-179 Administered Orally to Subjects With Solid Tumors
This is an open label dose escalation study to find the maximum tolerated dose (MTD) of PKI-179 in subjects with solid tumors. Part 1 of the study will be the dose estimation phase and will be open to subjects with all solid…
- Trial name
- NCT00997360
- Testing
- PKI-179
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Cancer, Solid Tumor
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
A Phase 1B/2A study will be conducted to establish safety and dose level of AMXT 1501 dicaprate in combination with IV DFMO, in cancer patients.
- Conditions
- Cancer, Solid Tumor, Solid Carcinoma, Advanced Cancer
- Trial name
- NCT05500508
- Testing
- AMXT1501, DFMO
- Where
- 7 sites in United States, Australia
- Volunteers
- 15 people
- Sponsor
- Aminex Therapeutics, Inc.
Advanced Malignant Solid Tumor, Solid Tumor Cancer
A First in Human Study of PLT012 in Participants With Solid Tumor Cancers
The goal of this clinical trial is to learn about what doses of PLT012 are safe to use in adults with advanced cancers in solid tumors. It will also learn about how effective different doses of PLT012 are in treating cancer.
- Trial name
- NCT07337525
- Testing
- PLT012
- Where
- 4 sites in United States
- Volunteers
- 36 people
- Sponsor
- Pilatus Biosciences Inc
Solid Tumor
Phase I Study VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Malignant Solid Tumors
This is a Phase 1, open-label, dose-escalation trial using standard 3+3 dose-escalation design in patients with advanced malignant solid tumors.
- Trial name
- NCT05266612
- Testing
- VG2025, Nivolumab Injection [Opdivo]
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Virogin Biotech Canada Ltd
Cancer
A Study of RO6927005 Either As Monotherapy (Part A) or in Combination With Gemcitabine and Nab-Paclitaxel (Part B) to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Clinical Activity in Patients With Mesothelin-positive Metastatic and/or Locally Advanced Malignant Solid Tumors
This is a first-in-human, open-label, multi-center, Phase 1 study of RO6927005. The study will establish the safety and tolerability profile of RO6927005 and will be conducted in two parts.
- Trial name
- NCT02317419
- Testing
- RO6927005, gemcitabine, nab-paclitaxel
- Where
- 6 sites in United States, Canada and 2 more
- Volunteers
- 15 people
- Sponsor
- Hoffmann-La Roche
Advanced Malignant Solid Tumor
A Study of MHB088C Combined With MHB039A in Patients With Advanced Malignant Solid Tumors
This is a first-in-human, open-label, multicenter Phase I/II study of MHB088C combined with MHB039A in patients with advanced malignant solid tumors.
- Trial name
- NCT07126665
- Testing
- MHB088C for Injection, MHB039A for Injection
- Where
- China
- Volunteers
- 116 people
- Sponsor
- Minghui Pharmaceutical (Hangzhou) Ltd